Ken Griffin Theravance Biopharma, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$7.66 - $10.25 $104,942 - $140,425	-13,700 Reduced 98.56%	200 $1,000
Q2 2024 Aug 14, 2024	BUY	$8.29 - $9.92 $103,624 - $124,000	12,500 Added 892.86%	13,900 $117,000
Q1 2024 May 15, 2024	SELL	$8.22 - $11.59 $25,482 - $35,929	-3,100 Reduced 68.89%	1,400 $12,000
Q4 2023 Feb 14, 2024	SELL	$8.58 - $11.4 $21,450 - $28,500	-2,500 Reduced 35.71%	4,500 $50,000
Q3 2023 Nov 14, 2023	SELL	$8.38 - $10.44 $31,844 - $39,672	-3,800 Reduced 35.19%	7,000 $60,000
Q2 2023 Aug 14, 2023	BUY	$10.16 - $11.92 $23,368 - $27,416	2,300 Added 27.06%	10,800 $111,000
Q1 2023 May 15, 2023	SELL	$9.87 - $11.44 $395,786 - $458,744	-40,100 Reduced 82.51%	8,500 $92,000
Q4 2022 Feb 14, 2023	BUY	$9.65 - $11.34 $295,290 - $347,004	30,600 Added 170.0%	48,600 $545,000
Q3 2022 Nov 14, 2022	BUY	$8.39 - $10.22 $67,120 - $81,760	8,000 Added 80.0%	18,000 $183,000

122

47.3M

200

12.8K

Ticker TBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,782,400
Market Cap $658M
Description
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.